Literature DB >> 2643338

Fasting and postabsorptive hepatic glucose and insulin metabolism in hyperthyroidism.

N Raboudi1, R Arem, R H Jones, Z Chap, J Pena, J Chou, J B Field.   

Abstract

The effect of thyroid hormone excess on hepatic glucose balances and fractional hepatic extraction of insulin and glucagon was examined in six conscious dogs with catheters in the portal vein, hepatic vein, and femoral artery and Doppler flow probes on the portal vein and hepatic artery. An oral glucose tolerance test was performed before and after the animals were made hyperthyroid by intramuscular thyroxine administration (100 micrograms.kg-1.day-1) for 10 days. In the basal state and after oral glucose, insulin and glucagon levels in the three vessels and the basal fractional hepatic extraction of insulin and glucagon were not significantly modified by thyroid hormone. These results suggest that in short-term thyrotoxicosis insulin secretion is not impaired, and the rise in fasting plasma glucose and increased hepatic glucose production could reflect hepatic insulin resistance, increased availability of precursors for gluconeogenesis, or increased glycogenolysis. Hyperthyroidism significantly increased basal flows in the portal vein (14.7 +/- 0.6 vs. 12.9 +/- 0.5 ml.kg-1.min-1), the hepatic artery (4.8 +/- 0.3 vs. 3.9 +/- 0.2 ml.kg-1.min-1) and vein (19.6 +/- 0.7 vs. 16.9 +/- 0.4 ml.kg-1.min-1), the fasting plasma glucose concentration (104 +/- 3 vs. 92 +/- 2 mg/dl), and basal hepatic glucose output (2.1 +/- 0.2 vs. 1.5 +/- 0.2 mg.kg-1.min-1). It did not alter the nonhepatic splanchnic uptake of glucose, the percent of orally administered glucose that appeared in the portal vein (47 +/- 2 vs. 45 +/- 11%), the percent of hepatic uptake of glucose (59 +/- 11 vs. 74 +/- 22%), or the shape of the glucose tolerance test.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2643338     DOI: 10.1152/ajpendo.1989.256.1.E159

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  Thyroid hormone receptor-β agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways.

Authors:  Daniel F Vatner; Dirk Weismann; Sara A Beddow; Naoki Kumashiro; Derek M Erion; Xiao-Hui Liao; Gary J Grover; Paul Webb; Kevin J Phillips; Roy E Weiss; Jonathan S Bogan; John Baxter; Gerald I Shulman; Varman T Samuel
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-05-07       Impact factor: 4.310

Review 2.  Thyroid hormone action in metabolic regulation.

Authors:  Yiyun Song; Xuan Yao; Hao Ying
Journal:  Protein Cell       Date:  2011-05-26       Impact factor: 14.870

3.  Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine.

Authors:  Francesco S Celi; Marina Zemskova; Joyce D Linderman; Sheila Smith; Bart Drinkard; Vandana Sachdev; Monica C Skarulis; Merel Kozlosky; Gyorgy Csako; Rene Costello; Frank Pucino
Journal:  J Clin Endocrinol Metab       Date:  2011-08-24       Impact factor: 5.958

Review 4.  Glucagon, cyclic AMP, and hepatic glucose mobilization: A half-century of uncertainty.

Authors:  Robert L Rodgers
Journal:  Physiol Rep       Date:  2022-05

5.  Association between altered thyroid state and insulin resistance.

Authors:  Kunal B Kapadia; Parloop A Bhatt; Jigna S Shah
Journal:  J Pharmacol Pharmacother       Date:  2012-04

6.  Cilnidipine and magnesium sulfate supplement ameliorates hyperglycemia, dyslipidemia and inhibits oxidative-stress in fructose-induced diabetic rats.

Authors:  Most Sumaiya Khatun Kali; Md Rafiqul Islam Khan; Ranjan Kumar Barman; Md Farhad Hossain; Mir Imam Ibne Wahed
Journal:  Heliyon       Date:  2021-12-26

7.  Association between thyroid hormones and insulin resistance indices based on the Korean National Health and Nutrition Examination Survey.

Authors:  Yun Mi Choi; Min Kyung Kim; Mi Kyung Kwak; Dooman Kim; Eun-Gyoung Hong
Journal:  Sci Rep       Date:  2021-11-05       Impact factor: 4.379

8.  Levothyroxine and insulin requirement in autoimmune polyglandular type 3 syndrome: a real-life study.

Authors:  V Guarnotta; G Pillitteri; G Gambino; S Radellini; E Vigneri; G Pizzolanti; C Giordano
Journal:  J Endocrinol Invest       Date:  2020-10-24       Impact factor: 4.256

9.  Transcriptional regulation of pyruvate dehydrogenase kinase.

Authors:  Ji Yun Jeong; Nam Ho Jeoung; Keun-Gyu Park; In-Kyu Lee
Journal:  Diabetes Metab J       Date:  2012-10-18       Impact factor: 5.376

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.